Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis
Recruiting now
Conditions studied: Pulmonary Fibrosis
In brief
This study is a prospective observational study for subjects with idiopathic pulmonary fibrosis (IPF) or non-IPF interstitial lung diseases (ILD). The purpose of this study is to compare whether imaging patterns from high-resolution computed tomography (HRCT) at baseline can predict worsening. Single Time point Prediction (STP) is a score derived from an artificial intelligenc/ machine learning (AI/ML) using the radiomic features from a HRCT scan that quantifies the imaging patterns of short-term predictive worsening.
Key facts
- Study ID
- NCT06162884
- Run by
- University of California, Los Angeles
- People needed
- 200
- Starts
- 2024-11-06
- Expected to finish
- 2029-08-19
- Last updated by the study team
- 2026-06-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may not qualify if…
- Planned to participate in an intervention trial within the next 6 months
- Currently listed for lung transplantation at the time of enrollment
- Malignancy, treated or untreated, other than malignancy unlikely to affect prognosis in the next 3 years such as skin cancer or non-metastatic prostate cancer within the past 5 years
- Any clinically significant co-morbidity, which in the view of investigator, is likely to contribute to mortality or ability to perform PFT's in the next 2 years
- Prebronchodilator Forced Expiratory Volume in 1 second (FEV1)/Forced vital capacity (FVC) <0.7 at as screening
- Exclusion of co-morbidities: congestive heart failure (stroke, deep vein thrombosis, pulmonary embolism, myocardial infarction), current virus-associated community acquired pneumonia, smoking-related chronic obstructive lung disease with FEV1 <70%, history of lung cancer, history of other cancer treated within the past 4 years for IPF and 5 years for non-IPF ILD (excluding basal cell carcinoma of skin).
- HRCT data from subjects with combined pulmonary fibrosis and emphysema (CPFE) can be collected.
- Major Discontinuing Criteria in this study
- lung transplant after baseline or death
- withdraw of consent or transition to another care center
Where it is running
- UCLA — Los Angeles, California, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.